Skip to content
Review Open access

A Multi‐Scale Computational Framework for Anti‐Persister Tuberculosis Drug Discovery

Oct 2026 · Chemical Biology and Drug Design · Vol 108 · 0 citations · 86 references
Medicine

TL;DR

A critically underexplored dimension, multi‐target drug discovery, is systematically examined, focusing on the design of dual‐pharmacophore inhibitors that simultaneously engage NDH‐2 and cytochrome bd oxidase, thereby raising the genetic barrier to resistance.

Abstract

Latent tuberculosis (TB), caused by dormant, non‐replicating Mycobacterium tuberculosis (Mtb), afflicts an estimated 1.7 billion individuals globally and remains a principal barrier to TB eradication. Dormant bacilli are phenotypically tolerant to conventional antibiotics and survive through continued dependence on oxidative phosphorylation (OXPHOS) and the electron transport chain (ETC), making bioenergetic enzymes, including the F1Fo‐ATP synthase, cytochrome bcc:aa3 supercomplex, Type II NADH dehydrogenase (NDH‐2) and cytochrome bd oxidase, compelling drug targets. This review proposes and rigorously analyses a synergistic, multi‐scale computational workflow as a uniquely powerful paradigm for discovering anti‐persister agents. The workflow cascades across four integrated stages: (1) dormancy‐specific Quantitative Structure–Activity Relationship (QSAR) modelling using hypoxic assay data, with predictive models achieving R2 values of 0.83–0.98; (2) rational scaffold design and pharmacophore‐guided hit expansion against structurally validated bioenergetic targets, incorporating bioisosteric replacement and fragment merging strategies; (3) structure‐based molecular docking exploiting high‐resolution cryo‐EM structures (resolution ≤ 2.67 Å), with clinically validated inhibitors such as Bedaquiline (BDQ) yielding docking scores of −12.3 to −15.8 kcal/mol; and (4) advanced Molecular Dynamics (MD) simulation under physiologically relevant conditions, including Constant pH MD (CpHMD) at phagosomal pH 4.5 and all‐atom mycomembrane models. A critically underexplored dimension, multi‐target drug discovery, is systematically examined, focusing on the design of dual‐pharmacophore inhibitors that simultaneously engage NDH‐2 and cytochrome bd oxidase, thereby raising the genetic barrier to resistance. By framing discovery as a logical progression from statistical correlation (QSAR) through structural hypotheses (scaffold design and docking) to dynamic atomistic validation (MD), this review provides a rigorous, quantitatively grounded computational roadmap for the next generation of anti‐persister therapeutics.

Read PDF

Similar papers

Review Open access Oct 2026

Research progress on the application of multi-scale computational methods in the research and development of anti-tuberculosis infection drugs

It is concluded that the top-down pipeline-spanning network pharmacology to ML, docking, and MD-integrated with bottom-up feedback constitutes a closed-loop paradigm that accelerates lead identification while addressing emergent drug resistance.

Ya-Jing Zhao, Chao Wang, Wen-Jing Shang et al. · 0 citations
Review Open access Oct 2026

Exploiting key metabolic pathways of Mycobacterium tuberculosis for next-generation anti-tubercular drug discovery

Mycobacterium tuberculosis (Mtb) caused disease Tuberculosis (TB) continues to be one of the leading causes of mortality although decades of medical research has progressed. With the alarming rise in multidrug-resistant and extensively drug-resistant strains, the effectiveness of conventional therapeutic regimens is be...

N. Parvin, K. Chanda, M. Balamurali · 0 citations
Open access Sep 2026

Exploration of novel anti-TB agents targeting the serine/threonine kinase enzyme (PknE) in Mycobacterium tuberculosis: an in silico study

A structure-based in silico workflow comprising virtual screening of 2,202 FDA-approved compounds, molecular docking, molecular docking, 300 ns molecular dynamics simulation, and in silico toxicity profiling provide a strong computational basis for repurposing these agents as adjunct anti-TB therapies, pending experime...

Abdallah Elssir Ahmed, Reem M. A. Ebrahim, N. M. Hajhamed et al. · 0 citations
Open access Oct 2026

Pathway-Based Analysis of Metabolic Enzymes as Drug Targets

The identification of PabB protein as an essential metabolic drug target, coupled with screening of FDA-approved drugs as inhibitors, provides a promising framework for anti tubercular drug discovery.

D. Bhat, Bhupender Singh · 0 citations
Open access Oct 2026

Natural Products as MexB‐specific Efflux Pump Inhibitors Against Pseudomonas aeruginosa

Antimicrobial resistance (AMR) remains a critical global health challenge, with the RND‐type MexAB–OprM efflux system of Pseudomonas aeruginosa playing a central role in intrinsic multidrug resistance (MDR) through the active extrusion of diverse antibiotics. In this study, we screened natural product libraries t...

Adarsha Sarmah, Anto Antony Selvaraj, N. Rameshkumar et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.